This site is intended for health professionals only

At the heart of general practice since 1960

Rosiglitazone gives better glycaemic control, but at a cost

Rosiglitazone achieves slightly better long-term glycaemic control in patients with type 2 diabetes than vildagliptin, but at the cost of increased weight, less favourable lipid profile, and higher risk for peripheral oedema.

A US study found 600 patients randomised to either rosiglitazone 8mg a day or vildagliptin 100mg a day showed a similar average reduction in HbA1c of 1.55% and 1.24% respectively.

But those taking rosiglitazone gained a significant 4.67kg more over the two year study period, had a 6.5% higher risk of peripheral oedema, and experienced 3.4% more serious adverse events than those in the vildagliptin group.

Diabetes Obes Metab 2009;11:571-578.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say